DPP4 and neoplasm: Consistent with these context-dependent effects, Zuo and colleagues (16) demonstrated that the DPP4 inhibitor anagliptin could be synergized with anti–PD-L1 therapy, as it reprogrammed tumor-associated macrophages, further underscoring that DPP4 function can vary with tumor context.